The EPS miss and widening losses are negative, but the stock's movement will hinge on Phase 3 catalyst timing and any data readouts at upcoming conferences (ATS May 15-20). Monitor for FDA meeting outcomes mid-2026 and potential partnership or financing needs given cash burn trajectory.
Price Chart
Executive Summary
Upstream Bio reported Q1 2026 EPS of -$0.79, missing consensus of -$0.75 by 5.3%, with net loss widening to $40.6M from $27.3M a year ago. The company is advancing Phase 3 plans for verekitug in severe asthma and CRSwNP with FDA meetings expected mid-2026 and Phase 3 initiations in Q1 2027, while capping enrollment in the COPD trial with data now expected in H2 2027. Cash of $294.6M funds operations through 2027, but the EPS miss and widening losses weigh on near-term sentiment.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.79 vs consensus -$0.75 (5.3% miss)
- Net loss widened to $40.6M from $27.3M in Q1 2025
- Cash, cash equivalents and short-term investments $294.6M as of March 31, 2026
- Phase 2 VENTURE COPD trial enrollment capped; data now expected H2 2027 (delayed from prior timeline)
- Phase 3 initiations in severe asthma and CRSwNP expected Q1 2027
- Research and development expenses increased 42% to $36.6M
Financial Impact
EPS miss of $0.04 per share; net loss increased $13.3M YoY
Risk Factors
- Clinical trial failure in Phase 3 severe asthma or CRSwNP
- Cash burn rate may require dilutive financing before Phase 3 data
- COPD trial delay to H2 2027 pushes back a key catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293845 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 8w ago | 8-K | $6.55 | awaiting T+60 | awaiting T+60 | $2.79 (−57.40%) |
Aug 11, 2026 11w ago | 8-K | $7.44 | awaiting T+60 | awaiting T+60 | $2.79 (−62.50%) |
Jun 17, 2026 18w ago | Insider Cluster | $6.25 | awaiting T+60 | awaiting T+60 | $2.79 (−55.36%) |
Jun 14, 2026 19w ago | Press Release | $6.10 $5.96 | ▼ −2.30% | ▼ −3.30% | $2.79 (−54.26%) |
May 18, 2026 23w ago | Press Release | $8.51 $6.91 | ▼ −18.80% | ▼ −23.65% | $2.79 (−67.22%) |
May 13, 2026 23w ago | Press Release | $9.36 $7.25 | ▲ +22.54% | ▲ +26.98% | $2.79 (+70.19%) |
Apr 17, 2026 27w ago | Press Release | $9.99 $7.14 | ▼ −28.53% | ▼ −34.67% | $2.79 (−72.07%) |
Mar 26, 2026 30w ago | 424B5 | $8.67 $6.41 | ▲ +26.07% | ▲ +42.13% | $2.79 (+67.82%) |
Mar 26, 2026 30w ago | Press Release | $9.79 $6.40 | ▼ −34.68% | ▼ −48.63% | $2.79 (−71.50%) |
Mar 16, 2026 32w ago | Insider Cluster | $9.61 $6.45 | ▼ −32.88% | ▼ −43.37% | $2.79 (−70.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers